Nothing Special   »   [go: up one dir, main page]

EA202090298A1 - METHODS FOR TREATMENT OF MUVOCISCIDOSIS - Google Patents

METHODS FOR TREATMENT OF MUVOCISCIDOSIS

Info

Publication number
EA202090298A1
EA202090298A1 EA202090298A EA202090298A EA202090298A1 EA 202090298 A1 EA202090298 A1 EA 202090298A1 EA 202090298 A EA202090298 A EA 202090298A EA 202090298 A EA202090298 A EA 202090298A EA 202090298 A1 EA202090298 A1 EA 202090298A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
muvociscidosis
compound
contained
Prior art date
Application number
EA202090298A
Other languages
Russian (ru)
Inventor
Эрик Л. Хейзелтайн
Сэмюэл Московитц
Сара Робертсон
Дэвид Уолтц
Вэйчао Джордж Чэнь
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Priority claimed from PCT/US2018/042486 external-priority patent/WO2019018395A1/en
Publication of EA202090298A1 publication Critical patent/EA202090298A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены соединение I формулыи/или фармацевтически приемлемая соль(и) соединения I, содержащееся в фармацевтической композиции, и способы его применения для лечения муковисцидоза.Compound I of the formula / / or a pharmaceutically acceptable salt (s) of compound I contained in a pharmaceutical composition and methods for its use for the treatment of cystic fibrosis are provided.

EA202090298A 2018-04-13 2018-07-17 METHODS FOR TREATMENT OF MUVOCISCIDOSIS EA202090298A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862657508P 2018-04-13 2018-04-13
PCT/US2018/042486 WO2019018395A1 (en) 2017-07-17 2018-07-17 Methods of treatment for cystic fibrosis

Publications (1)

Publication Number Publication Date
EA202090298A1 true EA202090298A1 (en) 2020-05-14

Family

ID=70847636

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090298A EA202090298A1 (en) 2018-04-13 2018-07-17 METHODS FOR TREATMENT OF MUVOCISCIDOSIS

Country Status (1)

Country Link
EA (1) EA202090298A1 (en)

Similar Documents

Publication Publication Date Title
NZ761388A (en) Methods of treatment for cystic fibrosis
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
EA202092490A1 (en) METHYL-MODIFYING ENZYMES MODULATORS, COMPOSITIONS AND THEIR APPLICATION
EP4331677A3 (en) Methods of treating feline coronavirus infections
MX2022006865A (en) Substituted tetrahydrofurans as modulators of sodium channels.
CO2019015090A2 (en) Treatment methods for cystic fibrosis
BR112019024525A2 (en) compound, pharmaceutically acceptable salt and pharmaceutical formulation of c12c kras inhibitors
EA202191361A1 (en) METHODS FOR TREATMENT OF MUCOVISCIDOSIS
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
MX2021004639A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors.
EA201791289A1 (en) INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS
EA201891377A1 (en) APPLICATION OF KV3.1 / Kv3.2 / Kv3.3 CHANNEL MODULATORS FOR PAIN TREATMENT
EA201892119A1 (en) DRUGS, OBTAINED BY COMBINING AGONIST FXR AND ARB
EA202191239A1 (en) COMPOUNDS AND THEIR APPLICATION FOR TREATMENT OF 1-ANTITRIPSIN DEFICIENCY
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201990765A1 (en) AZAINDAZOLE COMPOUNDS FOR USE IN DAMAGE OF THE TENDON AND / OR Ligaments
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
EA202190532A1 (en) ARGINASE INHIBITORS AND METHODS OF THEIR APPLICATION
EA201692300A1 (en) DERIVATIVES OF CARBOXAMIDE
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA201700356A1 (en) NEW CYCLOPROPANBENZOFURANILPYRIDOPYRAZINDIONS
EA201992233A1 (en) COMPOUNDS OF ISOXOXOLICARBOXAMIDE AND THEIR APPLICATION
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA202090164A1 (en) Isotretinoin oral-mucous compositions and methods for their use
EA201991570A1 (en) AMIDIC COMPOUNDS AND THEIR APPLICATION